Pharmacokinetic variability 225Ac and 213Bi from vector labeled 225Ac cancer therapy as a function of vector type (antibody vs. small molecule)

被引：0
|
作者：
Josefsson, Anders [2 ]
Nedrow, Jessie [2 ]
Ray, Sangeeta [2 ]
Bruchertseifer, Frank [1 ]
Morgenstern, Alfred [1 ]
Pomper, Martin [2 ]
Sgouros, George [2 ]
Hobbs, Robert [2 ]
机构：
[1] European Commiss, Joint Res Ctr, Directorate Nucl Safety & Secur, Karlsruhe, Germany
[2] Johns Hopkins Univ, Baltimore, MD USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2018年 / 59卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
137
引用
收藏
页数：2
相关论文
共 44 条
  • [21] 226Ra irradiation to produce 225Ac and 213Bi in an accelerator-driven system reactor
    Amer A. Al Qaaod
    Volodymyr Gulik
    Nuclear Science and Techniques, 2020, 31
  • [22] 226Ra irradiation to produce 225Ac and 213Bi in an accelerator-driven system reactor
    Al Qaaod, Amer A.
    Gulik, Volodymyr
    NUCLEAR SCIENCE AND TECHNIQUES, 2020, 31 (05)
  • [23] 226Ra irradiation to produce 225Ac and 213Bi in an accelerator-driven system reactor
    Amer A.Al Qaaod
    Volodymyr Gulik
    Nuclear Science and Techniques, 2020, 31 (05) : 14 - 19
  • [24] The Performance of two silica based ion exchange resins in the separation of 213Bi from its parent solution of 225AC
    Moore, Mark A.
    Counce, Robert M.
    Watson, Jack S.
    Hall, Howard
    APPLIED RADIATION AND ISOTOPES, 2018, 141 : 68 - 72
  • [25] Significant response to [225Ac]Ac-DOTATATE therapy in a patient with small cell lung cancer
    Tuncel, Murat
    Turkan, C.
    Eryilmaz, Y.
    Pala, A.
    Kilickap, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2025,
  • [26] Locoregional treatment of glioblastoma with targeted alpha therapy: [213Bi]Bi-DOTA-substance P vs [225Ac]Ac-DOTA-substance P - analysis of influence parameters
    Krolicki, L.
    Kunikowska, J.
    Bruchertseifer, F.
    Kulinski, R.
    Pawlak, D.
    Koziara, H.
    Rola, R.
    Morgenstern, A.
    Merlo, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S371 - S371
  • [27] Evaluation of an Anti-HER2 Nanobody Labeled with 225AC for Targeted α-Particle Therapy of Cancer
    Pruszynski, Marek
    D'Huyvetter, Matthias
    Bruchertseifer, Frank
    Morgenstern, Alfred
    Lahoutte, Tony
    MOLECULAR PHARMACEUTICS, 2018, 15 (04) : 1457 - 1466
  • [28] Dosimetry for Ac-225 and Bi-213 labeled cancer therapy agents
    Stabin, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [29] Locoregional Treatment of Glioblastoma With Targeted a Therapy [213Bi]Bi-DOTA-Substance P Versus [225Ac]Ac-DOTA-Substance P-Analysis of Influence Parameters
    Krolicki, Leszek
    Kunikowska, Jolanta
    Bruchertseifer, Frank
    Kulinski, Radoslaw
    Pawlak, Dariusz
    Koziara, Henryk
    Rola, Rafal
    Morgenstern, Alfred
    Merlo, Adrian
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (05) : 387 - 392
  • [30] Half-lives of 221Fr, 217At, 213Bi, 213Po and 209Pb from the 225Ac decay series
    Suliman, G.
    Pomme, S.
    Marouli, M.
    Van Ammel, R.
    Stroh, H.
    Jobbagy, V.
    Paepen, J.
    Dirican, A.
    Bruchertseifer, F.
    Apostolidis, C.
    Morgenstern, A.
    APPLIED RADIATION AND ISOTOPES, 2013, 77 : 32 - 37
12345